Palatin takes front seat in merger with Molecular Biosystems
This article was originally published in Clinica
Molecular Biosystems, maker of the FDA-approved Optison ultrasound contrast imaging agent, is to merge with a development-stage imaging agent company, Palatin Technologies, in a stock transaction valued at around $30 million. Upon completion, Palatin shareholders and the shareholders of Mallinckrodt, which has distribution arrangements and an equity stake in both companies, will each have around 50% of the new company.
You may also be interested in...
Unilever North America agrees SmartyPant, founded in 2011 to create a comprehensive supplement made from premium ingredients to support the wellbeing needs of children and adults. Kind, fully owned by Mars, has an agreement to acquire family-owned Nature's Bakery which offers snacks including fig bars and other soft-baked foods.
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.